ZYBT
Zhengye Biotechnology Holding Limited · NASDAQ
$1.50-0.02 (-1.64%)today
- Market cap
- $72.0M
- Prev close
- $1.52
52-week range15% up the range
$0.7$6.15
Zhengye Biotechnology Holding Limited (ZYBT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for ZYBT, including 1 SEC filing and 1 offering. The most recent was published Nov 12, 2026.
Price$1.50-0.03 (-2.28%)
2026-08-172026-11-17
Financial highlights
Full financials- Revenue, FY2025
- CN¥116.36M
- Revenue growth
- -37.6%
- Net income, FY2025
- -CN¥69.78M
- Net margin
- -60.0%
- Free cash flow, FY2025
- CN¥12.32M
- Cash
- CN¥50.33M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks13+100%
2026-05-242026-11-15
Mix290d
- SEC Filings1(50%)
- Offering1(50%)
Activity · 52 weeks2512 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRZhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026JILIN, China, Nov. 12, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its unaudited financial results for the six months ended June 30, 2026. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "During the first half of fiscal year 2026, we continued to enhance profitability through disciplined cost management and operational efficiency. Despite the decline in net revenue and gross profit, we are encouraged by the improvement in our gross pr
- SECSEC Form 6-K filed by Zhengye Biotechnology Holding Limited6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
- SECSEC Form 6-K filed by Zhengye Biotechnology Holding Limited6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
- PRZhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price RequirementJilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that on August 5, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on May 29, 2026, the Company received a notification letter from Nasdaq indicating t
- SECSEC Form 6-K filed by Zhengye Biotechnology Holding Limited6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
- PRZhengye Biotechnology Holding Limited Comments on Unusual Trading ActivityJilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today issued the following statement in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares. The Company does not normally comment on market activity or rumors. However, in light of the magnitude of the recent trading activity in the Company's securities, the Company is providing the following statement. The Company confirms that it is not a
- INSIDERNew insider Han Zhenfa claimed ownership of 42,963,748 units of Ordinary shares (SEC Form 3)3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cheng Yuhong (Nmn)3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Song Songlin3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wang Ping (Nmn)3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jiang Ping (Piji)3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- SECSEC Form 6-K filed by Zhengye Biotechnology Holding Limited6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
- PRZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to mai
- SECSEC Form 20-F filed by Zhengye Biotechnology Holding Limited20-F - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
- PRZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial ResultsJILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2025 was a year of resilience for Zhengye. While the broader hog market experienced low and volatile price fluctuations and government macro-control policies contributed to near-term pressure on swine vaccine demand, we remained focused on ex
- INSIDERSEC Form 3 filed by new insider Hu Qiyi3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Li Guohan (Nmn)3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- PRZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share StructureJilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced the implementation of a dual-class share structure, effective April 7, 2026. At the annual general meeting of shareholders held on March 24, 2026, the Company's shareholders approved the introduction of two classes of ordinary shares, designated as Class A and Class B. The Company's Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market at the open of
- INSIDERSEC Form 3 filed by new insider Lian Wei3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Liu Zhongyao3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sun Wenhua3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Han Aiden3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
- SECSEC Form 6-K filed by Zhengye Biotechnology Holding Limited6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
- PRZhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to ShareholdersJilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company's research and operational milestones achieved in 2025 and outlines Zhengye's strategic priorities for growth in 2026. The full text of the letter follows. Dear Shareholders, As we enter 2026, on behalf of the management of Zhengye
- SECSEC Form 6-K filed by Zhengye Biotechnology Holding Limited6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
ZYBT FAQ
9 questionsWhat is the latest news on ZYBT?
In the last 30 days Quantisnow tracked 2 wire items for ZYBT: 1 SEC filing and 1 offering. The most recent was published on November 12, 2026.What is ZYBT revenue?
Zhengye Biotechnology Holding Limited (ZYBT) reported CN¥116.36M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 37.6% from the year before.Is ZYBT profitable?
No. Zhengye Biotechnology Holding Limited reported a net loss of CN¥69.78M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ZYBT have?
Zhengye Biotechnology Holding Limited reported CN¥50.33M in cash and cash equivalents and CN¥9.55M of debt on its most recent balance sheet in SEC filings.Where does ZYBT stock trade?
Zhengye Biotechnology Holding Limited (ZYBT) is listed on NASDAQ.What sector and industry is ZYBT in?
Zhengye Biotechnology Holding Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zhengye Biotechnology Holding Limited go public?
Zhengye Biotechnology Holding Limited (ZYBT) completed its IPO in 2025.What companies are similar to ZYBT?
Notable peers in the same industry include MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson). Compare ZYBT side-by-side with any of them on Quantisnow.How can I track ZYBT on Quantisnow?
Quantisnow aggregates Zhengye Biotechnology Holding Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZYBT to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change